• SvenskaSvenska
Active Biotech
  • Home
  • About
    • Active Biotech in Brief
    • Board of Directors
    • Management
    • Business Concept
    • Corporate Governance
      • Corporate Governance Report 2019
      • Article of Association
      • Audit committee
      • Scientific committee
      • Election Committee
      • General Meetings
      • Auditors
    • Partnerships
    • Career
  • Projects
    • Project Overview
    • Naptumomab
    • Tasquinimod
    • Laquinimod
    • Patents
    • Orphan Drug Designation
  • Investor
    • Investor
    • Analyst coverage
    • Financial Calendar
    • Financial Reports
      • Interim Reports
      • Annual Reports
    • Stock
    • Ownership
    • Official Documents
      • Rights Issue 2014
      • Rights Issue 2016
      • Rights Issue 2018
      • Rights Issue 2021
  • Media
    • Press Contact
    • Press Releases
      • Subscribe
    • News
    • Company Presentation
    • Image Bank
  • Contact
Copyright © 2021 Active Biotech AB. All Rights Reserved.
Design by Clavis Communications.

Media

  • Press Contact
  • Press Releases
    • Subscribe
  • News
  • Company Presentation
  • Image Bank

Press Releases

  • Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference
    September 5, 2013 08:30 (CEST)
  • Active Biotech AB Interim Report January - June 2013
    August 7, 2013 08:30 (CEST)
  • TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS FROM PHASE IIa STUDY OF LAQUINIMOD IN ACTIVE LUPUS NEPHRITIS
    June 12, 2013 14:00 (CEST)
  • Impact of Active Biotech's candidate drug tasquinimod on bone metastases presented at ASCO
    June 3, 2013 15:00 (CEST)
  • Active Biotech's project ANYARA improved overall survival in a subgroup of renal cell cancer patients
    June 3, 2013 15:00 (CEST)
  • Active Biotech to Present at the Jefferies 2013 Global Healthcare Conference
    May 30, 2013 10:00 (CEST)
  • Annual General Meeting of Active Biotech AB
    May 16, 2013 08:30 (CEST)
  • New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology research
    May 16, 2013 08:30 (CEST)
  • Active Biotech AB Interim Report January - March 2013
    April 25, 2013 08:30 (CEST)
  • Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer
    April 25, 2013 07:00 (CEST)
  • <
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • >

Content

  • Home
  • About
  • Projects
  • Investor
  • Media
  • Contact

Postal Address

Active Biotech AB
P.O. Box 724
SE-220 07 Lund
Sweden

Visiting Address

Active Biotech AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

+46 46 19 20 00
info@activebiotech.com

LinkedIn

Copyright © 2021 Active Biotech AB. All Rights Reserved.
Design by Clavis Communications.
This site uses cookies.